Related Experiment Videos
VIM-D salvage chemotherapy in Hodgkin's disease
J K Phillips1, R L Spearing, J M Davies
1Department of Haematology, Royal Liverpool Hospital, England, UK.
Cancer Chemotherapy and Pharmacology
|January 1, 1990
Summary
The VIM-D regimen showed tolerability in treating relapsed Hodgkin
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Hodgkin's disease is a cancer of the lymphatic system.
- Relapsed or resistant Hodgkin's disease presents a treatment challenge.
Purpose of the Study:
- To evaluate the efficacy and tolerability of the VIM-D regimen in patients with relapsed or resistant Hodgkin's disease.
- To assess the impact of prior VIM-D exposure on autologous bone marrow transplant outcomes.
Main Methods:
- A total of 15 patients with relapsed/resistant Hodgkin's disease were treated with etoposide (VP16), ifosfamide, mitoxantrone, and dexamethasone (VIM-D).
- Toxicity, complete remission (CR) rates, and duration of remission were recorded.
- Subsequent autologous bone marrow transplant (ABMT) outcomes were analyzed in patients who received it.
Main Results:
- The VIM-D regimen was well tolerated, with myelosuppression as the primary toxicity.
- Four patients achieved complete remissions (CRs), maintained for 2-14 months.
- Ten patients underwent ABMT; prior VIM-D exposure did not negatively affect ABMT response.
Conclusions:
- The VIM-D regimen is a viable treatment option for relapsed or resistant Hodgkin's disease.
- VIM-D is generally well-tolerated, with manageable toxicity.
- Prior exposure to VIM-D does not preclude successful autologous bone marrow transplantation.